Biotechnology - Biotechnology, Markets & Marketing

Filter

Popular Filters

1 to 25 of 251 results

Merck enters lucrative cancer alliance with Pfizer

Merck enters lucrative cancer alliance with Pfizer

17-11-2014

Germany’s Merck KGaA said today that it has entered into a global agreement with US pharma giant Pfizer…

BiotechnologyGermanyLicensingMarkets & MarketingMerck KGaAMerck SeronoMSB0010718COncologyPfizerUSAXalkori

Advantages of Gilead’s Harvoni over emerging hepatitis C treatments

Advantages of Gilead’s Harvoni over emerging hepatitis C treatments

10-11-2014

US surveyed specialists anticipate prescribing Gilead Sciences’ Harvoni to a high proportion of their…

Anti-viralsBiotechnologyGilead SciencesHarvoniJanssenMarkets & MarketingMedivirOlysioSovaldiUSA

Increased scrutiny by EU5 health authorities will encourage off-label use of Avastin for wet-AMD

06-11-2014

Cost-constrained health authorities in the EU5 (France, Germany, Italy, Spain, and the UK) are increasingly…

AvastinBiosimilarsBiotechnologyEuropeFinancialLucentisMarkets & MarketingNovartisOphthalmicsRoche

Harvoni will keep Gilead atop hepatitis C treatment landscape, says analyst

Harvoni will keep Gilead atop hepatitis C treatment landscape, says analyst

23-10-2014

The recent US Food and Drug Administration approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’…

Anti-viralsBiotechnologyGilead SciencesHarvoniMarkets & MarketingPricingSovaldiUSA

Eurofins Genomics extends genomic business into Austria and Czech Republic

Eurofins Genomics extends genomic business into Austria and Czech Republic

21-10-2014

Eurofins Genomics, the genomics division of the Eurofins Scientific Group, and international market leader…

AustriaBiotechnologyEurofins GenomicsGeneticsMarkets & Marketing

Big Pharma's control over the Russian state drug procurement tenders market slipping away, says Biocad

16-10-2014

Russian pharmaceutical companies are actively squeezing out foreign therapeutic manufacturers from the…

AcellBiaBiocadBiosimilarsBiotechnologyMabTheraMarkets & MarketingOncologyRituxanRocheRussia

SOBI and Pharming extend and amend Ruconest agreement

SOBI and Pharming extend and amend Ruconest agreement

13-10-2014

Biotech companies Pharming Group and Swedish Orphan Biovitrum have amended and extended the Ruconest…

BiotechnologyHematologyMarkets & MarketingPharmingRuconestSobiSweden

Gilead looks set to stay ahead of the pack in HIV treatment market

Gilead looks set to stay ahead of the pack in HIV treatment market

09-10-2014

US biotech major Gilead Sciences’ announcement of positive Phase III results for its investigational…

Anti-viralsBiotechnologycobicistatelvitegravirEmtricitabine and Tenofovir Disoproxil FumaraGilead SciencesMarkets & MarketingResearchTriumeqUSAViiV Healthcare

Eurofins Genomics expands business into Italy

Eurofins Genomics expands business into Italy

01-10-2014

Eurofins Genomics, the genomics division of Eurofins Scientific Group, has expanded its business into…

BiotechnologyEurofins GenomicsGeneticsItalyMarkets & Marketing

Biosimilars set to revolutionize global drug development industry, says report

Biosimilars set to revolutionize global drug development industry, says report

30-09-2014

Intellectual Property and Science business of Thomson Reuters today announced the release of Biosimilars:…

BiosimilarsBiotechnologyGlobalMarkets & MarketingResearch

Premium-price biologicals and novel therapies will drive psoriatic arthritis market growth

10-09-2014

The market for psoriatic arthritis (PsA) therapies will grow nearly 66%, increasing to $3.7 billion in…

AbbVieAmgenAnti-Arthritics/RheumaticsBiosimilarsBiotechnologyEli LillyEuropeHumiraJapanMarkets & MarketingNovartisOtezlaStelaraUSAXeljanz

NSCLC treatment market set to grow to more than $7.9 billion by 2020

NSCLC treatment market set to grow to more than $7.9 billion by 2020

09-09-2014

The global non-small cell lung cancer treatment market value will increase from $5.1 billion in 2013…

BiotechnologyBoehringer IngelheimBristol-Myers SquibbEli LillyGilotrifGlobalMarkets & MarketingnecitumumabnivolumabOncologyYervoy

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report

09-09-2014

The recent US Food and Drug Administration and European Commission approval of HIV specialist ViiV Healthcare’s…

Anti-viralsAtriplaBiotechnologyGilead SciencesGlobalDataHIVMarkets & MarketingStribildTriumeqUSAViiV Healthcare

China monoclonal antibody research forecast to increase

China monoclonal antibody research forecast to increase

28-08-2014

Several Chinese large-scale pharmaceutical enterprises have devoted themselves to research and development…

BiosimilarsBiotechnologyChinaHengrui MedicineMarkets & MarketingQilu PharmResearchShanghai Pharmaceuticals

Amgen issues voluntary recall of Aranesp prefilled syringes in certain countries

Amgen issues voluntary recall of Aranesp prefilled syringes in certain countries

15-08-2014

USA-based Amgen initiated a voluntary recall on June 26 for nine packaged lots of anemia drug Aranesp…

AmgenAnemiaAranespBiotechnologyMarkets & MarketingOncologyRegulation

New drugs to boost graft-versus-host disease treatment market by 2018

New drugs to boost graft-versus-host disease treatment market by 2018

15-08-2014

The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to…

Adienne PharmaBegedinaBiotechnologyBudenofalkDr Falk PharmaEuropeImmunologicalsJazz PharmaceuticalsMarkets & MarketingMesoblastProchymalUSA

Biogen Idec’s long-acting agents to have major impact on hemophilia market

Biogen Idec’s long-acting agents to have major impact on hemophilia market

14-08-2014

The hemophilia treatment landscape is to undergo a radical shift away from established short-acting therapies,…

AlprolixBiogen IdecBiotechnologyCoagulation systemEloctateEuropeHematologyHemophilia treatmentJapanMarkets & MarketingRecombinant proteinsRFIX productsSwedish Orphan BiovitrumUSA

Vertex to drop hep C drug Incivek following poor sales

14-08-2014

Struggling US Biotech firm Vertex Pharmaceuticals has said it will cease marketing its hepatitis C treatment…

Anti-viralsBiotechnologyGilead SciencesHepatitis C treatmentIncivekJohnson & JohnsonMarkets & MarketingSovaldiTelaprevirUSAVertex Pharmaceuticals

Sanofi and PATH the first to bring large quantities of semisynthetic artemisinin antimalarial treatment to market

Sanofi and PATH the first to bring large quantities of semisynthetic artemisinin antimalarial treatment to market

12-08-2014

French drug major Sanofi and Seattle-based PATH have become the first to deliver large-scale batches…

Anti-viralsartemisininBiotechnologyMarkets & MarketingPATHSanofiUSA

3SBio enters patent license agreement with DiNonA for Leukotuximab

3SBio enters patent license agreement with DiNonA for Leukotuximab

08-08-2014

Chinese biotechnology company 3SBio has entered into an exclusive license with Korean DiNonA for the…

3SBioBiotechnologyChinaDiNonAKoreaLeukemiaLeukotuximabLymphocytic leukemiaManufacturingMarkets & MarketingOncology

Amgen’s evolocumab to become gold standard among add-on statin therapies

Amgen’s evolocumab to become gold standard among add-on statin therapies

22-07-2014

Leading independent biotech firm Amgen’s investigational compound evolocumab (AMG-145) is set to become…

AmgenBiotechnologyCardio-vascularCardiovascular diseaseEuropeevolocumabMarkets & MarketingUSA

BioAlliance’s Sitavig debuts in USA; new patent granted

BioAlliance’s Sitavig debuts in USA; new patent granted

22-07-2014

French drug developer BioAlliance Pharma says that its US partner Innocutis Holdings has launched Sitavig…

Anti-viralsBioAlliance PharmaBiotechnologyHealth Medical PharmaHerpesInnocutis HoldingsLabial herpesMarkets & MarketingMedicineMicrobiologyPatentsSitavigUSA

Global regenerative medicine market expected to reach $67 billion by 2020

Global regenerative medicine market expected to reach $67 billion by 2020

15-07-2014

The global regenerative medicine market will reach $67.6 billion by 2020, up from $16.4 billion in 2013…

BiotechnologyGlobalImmunologicalsMarkets & MarketingRegenerative medicineResearchStem cells

Will innovations in biomarkers lead to a paradigm shift in drug discovery?

01-07-2014

With the efficacy for most drugs targeting severe therapeutic indications ranging from a meagre 25% to…

BiotechnologyEuropeMarkets & MarketingResearch

1 to 25 of 251 results

Back to top